Sebum Metabolomics and Lipidomics for Clinical Applications

NCT07549828 | Not Yet Recruiting

• 1 other identifier: 202602076RINB
• Study Type: interventional
• Target: 200
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study aims to develop a standardized workflow for sebum sampling and metabolomics/lipidomics analysis using Sebutape. A total of 200 participants will be recruited, including healthy individuals, patients with skin diseases, individuals undergoing dermatological treatments or using skincare products, and a subset of healthy participants receiving short-term topical antibiotic intervention. The study will investigate sebum composition, skin microbiome profiles, and their interactions under different conditions to explore potential biomarkers and clinical applications.

Conditions

Acne; Atopic Dermatitis; Psoriasis; Healthy Subjects (HS); Seborrheic Dermatitis

Keywords

Sebum; Lipidomics; Metabolomics; Skin microbiome; Sebutape; LC-MS/MS

Outcome Measures

Primary Outcomes (2)

• Concentration of Sebum Lipids Measured by LC-MS/MS

  Sebum lipid levels will be measured using Sebutape sampling followed by LC-MS/MS analysis. Results will be reported as normalized intensity.

  From baseline (pre-intervention or pre-treatment) to post-intervention (approximately 1 day after completion of a 3-day intervention) or post-treatment (up to 3 months after treatment initiation, depending on treatment regimen)

• Relative Abundance of Skin Microbiome Composition Assessed by Sequencing

  Skin microbiome profiles will be assessed using sequencing-based analysis and reported as relative abundance (%).

  From baseline (pre-intervention or pre-treatment) to post-intervention (approximately 1 day after completion of a 3-day intervention) or post-treatment (up to 3 months after treatment initiation, depending on treatment regimen)

Study Arms (1)

Sebutape sampling and analysis

EXPERIMENTAL

All participants will undergo non-invasive sebum sampling using Sebutape. Samples will be analyzed for metabolomic and lipidomic profiles using LC-MS/MS, and microbiome profiling will be performed using 16S rRNA sequencing. Subgroups include healthy individuals, patients with skin diseases, individuals undergoing dermatological treatments or using skincare products, and a subset of healthy participants receiving short-term topical antibiotic intervention.

Other: Sebutape sampling; Drug: Bacitracin/Polymyxin B/Neomycin ointment (Yentuogin ointment)

Interventions

Sebutape sampling OTHER

Non-invasive sebum sampling using Sebutape patches. Each participant will undergo standardized sampling procedures, with one patch used for metabolomics/lipidomics analysis and another for microbiome profiling. Samples will be stored at -80 °C for subsequent LC-MS/MS and 16S rRNA sequencing.

Sebutape sampling and analysis

Bacitracin/Polymyxin B/Neomycin ointment (Yentuogin ointment) DRUG

Short-term topical antibiotic intervention using Yentuogin ointment containing Bacitracin, Polymyxin B, and Neomycin. Healthy participants will apply the ointment 1-2 times daily for up to 3 days. Sebutape samples will be collected before and after intervention to assess changes in sebum composition and skin microbiome.

Sebutape sampling and analysis

Eligibility Criteria

• Age: 20 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Individuals aged ≥20 years, regardless of sex or ethnicity, and assessed by the investigator to be in good health and suitable for participation.
• No diagnosed skin diseases or chronic systemic diseases.
• No use of medications or receipt of dermatological treatments that may affect sebum secretion or the skin microbiome within the past two weeks.

You may not qualify if:

• Known allergy to Sebutape or similar adhesive tapes, or a history of related adverse reactions.
• Presence of acute or chronic skin diseases, or chronic systemic diseases.
• Use of medications or receipt of dermatological treatments that may affect sebum secretion or the skin microbiome within the past two weeks.
• Use of lotions, sunscreen, or other skincare products that may affect skin condition within 12 hours prior to sampling.
• Any other conditions deemed unsuitable for participation by the principal investigator.
• B. Participants with Skin Diseases or Specific Skin Conditions
• Individuals aged ≥20 years, regardless of sex or ethnicity, and assessed by the investigator to be suitable for participation.
• Diagnosed by a physician or clinically assessed as having one of the following:
• Acne
• Atopic dermatitis
• Seborrheic dermatitis
• Psoriasis
• Other common skin diseases
• Specific skin conditions (e.g., postmenopausal or aging-related skin changes)
• Known allergy to Sebutape or similar adhesive tapes, or a history of related adverse reactions.

Sponsors & Collaborators

• National Taiwan University Hospital: lead

MeSH Terms

Conditions

Acne Vulgaris; Dermatitis, Atopic; Dermatitis, Seborrheic; Psoriasis

Interventions

Bacitracin

Condition Hierarchy (Ancestors)

Acneiform Eruptions; Skin Diseases; Skin and Connective Tissue Diseases; Sebaceous Gland Diseases; Skin Diseases, Genetic; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Dermatitis; Skin Diseases, Eczematous; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases; Skin Diseases, Papulosquamous

Intervention Hierarchy (Ancestors)

Peptides, Cyclic; Macrocyclic Compounds; Polycyclic Compounds; Peptides; Amino Acids, Peptides, and Proteins

Study Officials

• Ching_Hua Kuo

  National Taiwan University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Ya-Chu Kuo, PhD

CONTACT

+886-2-3366-8766; iris890402@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 6, 2026
• First Posted: April 24, 2026
• Study Start: April 1, 2026
• Primary Completion (Estimated): March 31, 2029
• Study Completion (Estimated): March 31, 2029
• Last Updated: April 24, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share